Jaws Acquisition Corp. (Form: 8-K, Received: 05/28/2021 17:24:57)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 28, 2021

JAWS ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Cayman Islands

001-39289

98-154224

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1601 Washington Avenue, Suite 800

Miami Beach, FL 33139

(Address of principal executive offices, including Zip Code)

(203) 422-7718

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-third of one redeemable warrant	JWS.U	New York Stock Exchange
Class A ordinary shares included as part of the units	JWS	New York Stock Exchange
Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50	JWS WS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 1.01

Entry Into A Material Definitive Agreement

As previously disclosed, on November 11, 2020, Jaws Acquisition Corp., a Cayman Islands exempted company (“Jaws”), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among JAWS, Jaws Merger Sub, LLC, a Delaware limited liability company (“Merger Sub”), Primary Care (ITC) Holdings, LLC, a Delaware limited liability company (the “Seller”), and Primary Care (ITC) Intermediate Holdings, LLC, a Delaware limited liability company (the “Company”). A copy of the Business Combination Agreement was attached as Exhibit 2.1 to Jaws’ Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 12, 2020. Capitalized terms used but not defined herein shall have the meaning ascribed to such term in the Business Combination Agreement.

On May 28, 2021, Jaws, Merger Sub, the Seller and the Company entered into an Amendment to Business Combination Agreement (the “Amendment”). The Amendment (i) provides that a different directors’ and officers’ liability insurance policy may be purchased and maintained in lieu of the Company D&O Tail Policy (as defined in the Business Combination Agreement), (ii) removes Stephen Haft, the Company’s prior CFO, and adds Brian D. Koppy, the Company’s new CFO, to the definition of Other Investor Agreement Parties, (iii) updates the list of Lock-Up Seller Unitholders on Annex C of the Business Combination Agreement to remove certain persons and entities who will not be shareholders of the Company as of the Closing, and (iv) corrects a scrivener’s error in Section 2.1(a) of the Business Combination Agreement relating to the process by which JAWS will redomesticate into Delaware prior to the Effective Time. A copy of the Amendment is filed with this Current Report on Form 8-K as Exhibit 2.1 and is incorporated herein by reference, and the foregoing description of the Amendment is qualified in its entirety by reference thereto.

Additional Information

Jaws has filed, and the SEC has declared effective, a registration statement on Form S-4 containing a definitive proxy statement/prospectus of Jaws relating to the proposed transactions contemplated by the Business Combination Agreement (together, the “Business Combination”). Jaws has mailed the definitive proxy statement/prospectus and other relevant documents to its shareholders. Investors, Jaws’ shareholders and other interested persons are advised to read the definitive proxy statement/prospectus in connection with Jaws’ solicitation of proxies for the General Meeting to be held to approve the Business Combination as these materials will contain important information about the Company and Jaws and the proposed Business Combination. The definitive proxy statement/prospectus has been mailed to the shareholders of Jaws as of the record date of March 24, 2021; shareholders that hold their shares in registered form are entitled to vote their shares held on the date of the meeting. Shareholders are also able to obtain copies of the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, at the SEC’s website at http://www.sec.gov, or by directing a request to: Jaws Acquisition Corp., 1601 Washington Avenue, Suite 800, Miami Beach, FL 33139.

Participants in the Solicitation

Jaws and its directors and executive officers may be deemed participants in the solicitation of proxies from Jaws’ shareholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in Jaws is contained in the definitive proxy statement, which was filed with the SEC and is available free of charge at the SEC’s website at www.sec.gov, or by directing a request to Jaws Acquisition Corp., 1601 Washington Avenue, Suite 800, Miami Beach, FL 33139.

The Company and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Jaws in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination is included in the definitive proxy statement/prospectus for the Business Combination.

Forward-Looking Statements

Certain statements in this Current Report on Form 8-K may be considered forward-looking statements. Forward-looking statements generally relate to future events or Jaws’ or the Company’s future financial or operating performance. For example, projections of future growth, financial performance, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Jaws and its management, and the Company and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against Jaws, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of Jaws, to obtain financing to complete the Business Combination or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability to meet stock exchange listing standards at or following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of the Company as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination; (9) changes in applicable laws or regulations; (10) the possibility that the Company or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the Company’s estimates of expenses and profitability; and (12) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Jaws’ final prospectus relating to its initial public offering, dated May 13, 2020, subsequent quarterly reports on form 10-Q and amended proxy statement, filed with the SEC on April 2, 2021 in connection with the Business Combination.

Nothing in this Current Report on Form 8-K should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Jaws nor the Company undertakes any duty to update these forward-looking statements.

No Offer or Solicitation

This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Jaws or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K.


Exhibit No.		Description
2.1		Amendment to Business Combination Agreement, dated May 28, 2021

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	JAWS ACQUISITION CORP.

Date: May 28, 2021	By:	/s/ Mike Racich
	Name: Mike Racich
	Title: Chief Financial Officer

Exhibit 2.1

AMENDMENT

BUSINESS COMBINATION AGREEMENT

DATED: May 28, 2021

This AMENDMENT (this “Amendment”), to that certain Business Combination Agreement (as may be further amended or modified from time to time, the “Agreement”), dated as of November 11, 2020, is entered into by and among Jaws Acquisition Corp., a Cayman Islands exempted company (“JAWS”), Jaws Merger Sub, LLC, a Delaware limited liability company (“Merger Sub”), Primary Care (ITC) Holdings, LLC, a Delaware limited liability company (the “Seller”), and Primary Care (ITC) Intermediate Holdings, LLC, a Delaware limited liability company (the “Company”), and is effective as of the date first set forth above. JAWS, Merger Sub, Seller and the Company shall be referred to herein from time to time collectively as the “Parties” and each individually as a “Party”. Any capitalized term used but not defined in this Amendment shall have the meaning ascribed to such term in the Agreement.

RECITALS

WHEREAS, Section 9.3 of the Agreement provides that the Agreement may be amended or modified only by a written agreement executed and delivered by the Parties; and

WHEREAS, the Parties desire to modify and amend the Agreement as set forth in this Amendment.

NOW, THEREFORE, in consideration of the promises and the mutual agreements and covenants hereinafter set forth, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows:

AMENDMENT

1. Section 2.1(a) of the Agreement is hereby amended by deleting the proviso at the end of such Section and replacing it with the following:

“; provided, however, that, in connection with clause (i) and (ii), each issued and outstanding unit of JAWS that has not been previously separated into the underlying JAWS Class A Shares and underlying JAWS Warrants prior to the Domestication shall, for the avoidance of doubt, be cancelled and will entitle the holder thereof to one share of New JAWS Class A Shares and one-third of one New JAWS Warrant on the terms and subject to the conditions set forth in the Warrant Agreement, as applicable.”

2. Section 5.14(c) of the Agreement is hereby amended to add the following immediately following the last sentence of Section 5.14(c) of the Agreement:

“Notwithstanding the foregoing in this Section 5.14(c), in lieu of the Company purchasing, and New JAWS maintaining, the Company D&O Tail Policy, Seller, in its sole discretion, may cause the Company to purchase, and New JAWS shall maintain, for a period of six (6) years after the Effective Time, without lapses in coverage, as part of New JAWS’ (and/or the Group Companies’) insurance policies following the Effective Time, directors’ and officers’ liability insurance coverage for the benefit of those Persons who are currently covered by any comparable insurance policies of the Group Companies as of the date of this Agreement with respect to matters occurring on or prior to the Effective Time on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under the Group Companies’ directors’ and officers’ liability insurance policies as of the date of this Agreement; provided that none of the Company, New JAWS or any of their respective Affiliates shall pay a premium for such coverage of matters occurring on or prior to the Effective Time in excess of three hundred percent (300%) of the most recent annual premium paid by the Group Companies prior to the date of this Agreement and, in such event, the Company, New JAWS or one of their respective Affiliates shall purchase the maximum coverage available for three hundred percent (300%) of the most recent annual premium paid by the Group Companies prior to the date of this Agreement. Prior to obtaining such coverage, Seller and the Company shall cooperate with JAWS and keep them reasonably informed, including with respect to the terms, scope, costs and status of such coverage.”

3. The definition of “Other Investor Agreement Parties” in Section 1.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

“Other Investor Agreement Parties” means each of InTandem, Cano America, Dr. Marlow Hernandez, Dr. Richard Aguilar, David Armstrong, Brian D. Koppy and each of the directors of New JAWS immediately after the Effective Time.

4. Annex C of the Agreement is hereby amended to remove and delete each of “Enrique Zamora” and “Belen Medical Centers, LLC”.

5. Except as expressly set forth herein, this Amendment shall not by implication or otherwise alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Agreement, all of which shall remain in full force and effect.

6. Article 9 of the Agreement is hereby incorporated herein by reference, mutatis mutandis.

[Signature Page Follows]

IN WITNESS WHEREOF the Parties have caused this Amendment to be executed as of the date first set forth above by their duly authorized representatives.


JAWS ACQUISITION CORP.

By:		/s/ Mike Racich
Name:		Mike Racich
Title:		Chief Financial Officer

JAWS MERGER SUB, LLC

By:		/s/ Mike Racich
Name:		Mike Racich
Title:		Authorized Person

PRIMARY CARE (ITC) HOLDINGS, LLC

By:		/s/ Elliot Cooperstone
Name:		Elliot Cooperstone
Title:		Manager

PRIMARY CARE (ITC) INTERMEDIATE HOLDINGS, LLC

By:		/s/ Marlow Hernandez
Name:		Marlow Hernandez
Title:		Chief Executive Officer

[Signature Page to Amendment to Business Combination Agreement]